Publications by authors named "Z Nitsan"
Article Synopsis
- Current estimates of genetic variants linked to Parkinson's disease (PD) show limitations and biases across different populations, complicating patient recruitment for clinical trials focused on genetic therapies.
- The Rostock Parkinson's disease (ROPAD) study analyzes data from 12,580 PD patients across 16 countries, revealing that 14.8% had a genetic test positive for PD-related variants, particularly in specific genes like GBA1 and LRRK2.
- Findings indicate higher positivity rates in patients with earlier onset (age ≤ 50) or a positive family history, emphasizing the need for more extensive genetic investigation to improve patient stratification for future clinical trials.
Background: Creutzfeldt-Jakob disease (CJD) is a fatal neurodegenerative disease characterized by rapidly progressive dementia, motor impairments, and psychiatric symptoms. Sensory disturbances were occasionally reported as well. The study aims to describe the sensory symptoms of the disease.
View Article and Find Full Text PDFArticle Synopsis
- The study examines demographic and clinical features of young-onset Creutzfeldt-Jakob disease (CJD) by comparing patients under 40 years old to older patients.
- The analysis of 731 CJD patients revealed that older patients showed more typical MRI findings and presented with rapidly progressive dementia more frequently, while younger patients had higher instances of cerebellar symptoms.
- The findings suggest that young-onset genetic CJD patients exhibit distinct characteristics, such as atypical MRI results and a lower occurrence of dementia at the onset of the disease.
The consequences of switching from Gilenya® to generics for fingolimod.
Mult Scler Relat Disord
June 2023
Background: On May 2017, two generic drugs for fingolimod were introduced into the market in Israel, and most MS patients treated with Gilenya® (Novartis) were switched to fingolimod (Teva), or to Finolim (Rafa). In this study we analyzed the consequences of switching to generic fingolimod in a single MS center.
Methods: Study population included relapsing MS patients who were treated with Gilenya® for at least two year before May 2017, switched to generic fingolimod and remained on treatment for at least 2 years thereafter.
Parkinson's disease (PD) is taking a staggering toll on healthcare systems worldwide, with the bulk of the expenditures invested in the late stages of the disease. Considering the rising life expectancy and the increasing prevalence of PD across the globe, a clear understanding of the early signs and treatment options available for advanced PD (APD), will facilitate tailoring management programs and support services. This task is complicated by the lack of both global consensus in defining APD and standardized care guidelines.
View Article and Find Full Text PDF